Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the In-vitro Colorectal Cancer Screening Tests Sector?
In recent years, the market size for in-vitro colorectal cancer screening tests has seen significant expansion. The market, valued at $1.21 billion in 2024, is projected to increase to $1.30 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. Factors contributing to this upward trend include heightened awareness of the benefits of early cancer detection, the establishment of more governmental screening initiatives, a rise in the use of non-invasive testing procedures, increased investment in healthcare, and a greater accessibility to home screening kits.
The market size for in-vitro colorectal cancer screening tests is anticipated to experience robust growth in the coming years, expanding to a worth of $1.71 billion by 2029 with a compound annual growth rate (CAGR) of 7.0%. This anticipated growth within the forecasted period can be credited to enhancing focus on personalised medicine, an escalating demand for affordable diagnostics, burgeoning investments in cancer research, rising uptake of molecular diagnostic methodologies, an increasing occurrence of colorectal cancer, and improving availability of tests in emerging markets. The foreseen period also suggests significant trends including advancements in liquid biopsy technology, inventive breakthroughs in biomarker discovery, incorporation of artificial intelligence in test evaluation, sophisticated progress in multi-target stool deoxyribonucleic acid tests, innovations in specimen collection and processing, progressions in automation and digital pathology, and the inclusion of cloud-based diagnostic platforms.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27319&type=smp
What Forces Are Driving The Growth Of The In-vitro Colorectal Cancer Screening Tests Market?
The escalating rates of colorectal cancer are anticipated to drive the expansion of the in vitro colorectal cancer screening tests market. This form of cancer primarily initiates in the colon or rectum and is often a progression from precancerous polyps. Lifestyle habits that are detrimental to health, such as poor eating patterns, sedentary behavior, and obesity, amplify the risk of polyp creation and cancer progression. In vitro colorectal cancer screening tests facilitate colorectal cancer diagnosis by providing non-invasive procedures to recognize the early indicators of cancer. These tests enhance screening precision through sophisticated biomarker detection, improving early treatment and patient results. For example, in February 2025, the American Cancer Society, a nonprofit organization based in the US, estimated that the number of fresh colorectal cancer cases had surged to 154,270, marking an upswing from 152,810 in 2024. Hence, the escalating rates of colorectal cancer are fueling the expansion of the in vitro colorectal cancer screening tests market.
How Is The In-vitro Colorectal Cancer Screening Tests Industry Segmented Across Key Parameters?
The in-vitro colorectal cancer screening tests market covered in this report is segmented
1) By Test Type: Fecal Occult Blood Test, Stool Deoxyribonucleic Acid Test, Blood Biomarker Test, Other Test Types
2) By Imaging Type: Colonoscopy, Proctoscopy, Computed Tomography Scan, Ultrasound, Magnetic Resonance Imaging, Positron Emission Tomography Scan
3) By Application: Screening, Diagnosis, Monitoring, Risk Assessment, Post-Treatment Surveillance
4) By End User: Hospitals, Diagnostic Laboratories, Outpatient Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Fecal Occult Blood Test: Guaiac Based Fecal Occult Blood Test, Immunochemical Fecal Occult Blood Test
2) By Stool Deoxyribonucleic Acid Test: Single Target Stool Deoxyribonucleic Acid Test, Multi Target Stool Deoxyribonucleic Acid Test
3) By Blood Biomarker Test: Methylated Septin 9 Deoxyribonucleic Acid Test, Circulating Tumor Deoxyribonucleic Acid Test, Protein Biomarker Based Blood Test
4) By Other Test Types: Urine Based Biomarker Test, Serum Based Biomarker Test, Breath Based Volatile Organic Compound Test
What Notable Trends Are Shaping The Direction Of The In-vitro Colorectal Cancer Screening Tests Market?
In the market of in vitro colorectal cancer screening tests, significant companies are prioritizing the development of sophisticated diagnostic alternatives such as multi-target stool DNA tests. These efforts aim to enhance early detection precision, make testing more convenient for patients and decrease mortality rates resulting from colorectal cancer. Multi-target stool DNA testing is a cutting-edge screening method that examines stool specimens for the presence of genetic and biochemical markers linked to colorectal cancer and pre-cancerous growths. For example, Exact Sciences Corp – a molecular diagnostics corporation based in the USA – introduced Cologuard Plus in March 2025. This enhanced at-home testing option is intended for adults at an average risk, who are 45 or older. The test implements superior biomarker technology, providing a higher accuracy and specificity compared to the previous version. The approach refines the algorithm crucial for spotting DNA mutations and hemoglobin biomarkers, which enhances detection of colorectal cancer and developed adenomas. By offering a non-invasive, convenient screening solution, Cologuard Plus eliminates the need for bowel preparation and dietary restrictions and effectively boosts patient compliance with advised screening protocols.
Which Companies Currently Dominate The Competitive Landscape In The In-vitro Colorectal Cancer Screening Tests Industry?
Major companies operating in the in-vitro colorectal cancer screening tests market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Quest Diagnostics Incorporated, Roche Diagnostics International AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Natera Inc., Leica Biosystems Nussloch GmbH, BGI Genomics Co. Ltd., NeoGenomics Inc., Guardant Health Inc., CellMax Life Inc., Epigenomics AG, Acuamark Diagnostics Inc., Beacon Biomedical Inc., Mainz Biomed NV.
Get The Full Report Here:
Which Geographic Regions Are Driving Demand In The In-vitro Colorectal Cancer Screening Tests Market?
North America was the largest region in the in-vitro colorectal cancer screening tests market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro colorectal cancer screening tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27319&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model